ArticleFrontiers in public health2023
Antimicrobial resistance in
Article in Frontiers in public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Convergence of Antimicrobial Resistance and Virulence inMicroorganisms · 2026Review
- Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026Review
- Pre and post introduction of pneumococcal conjugate vaccines in children in Eastern Mediterranean Region and effect on antimicrobial resistance, a narrative review.Frontiers in microbiology · 2026Review
- Genomic epidemiology ofFrontiers in cellular and infection microbiology · 2026Article
- Impact of COVID-19 on Invasive Pneumococcal Disease: A Comparative Analysis of Clinical Features and Antibiotic Resistance across Pandemic Periods.Infection & chemotherapy · 2025Article
- Time to death and its predictors among under-five children with acute pneumonia: a Bayesian parametric survival analysis.Pneumonia (Nathan Qld.) · 2025Article
- Strategies for the Prevention and Management of Respiratory Infections in Patients at High Risk in the UAE: A Cross-Disciplinary Position Paper.Pulmonary therapy · 2025Review
- Genomic surveillance of invasiveMicrobial genomics · 2025Article
- Unveiling the impact: COVID-19's influence on bacterial resistance in the Kingdom of Bahrain.World journal of virology · 2025Article
- The Evolution of the Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Invasive pneumococcal disease in the Gulf region: a narrative review of incidence, burden, and vaccine strategies.Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although pneumococcal conjugate vaccines (PCV) have been effective in reducing the burden of Methods: Retrospective analysis of Results: From 2010 to 2021, 11,242 non-duplicate Conclusion: The increasing trend of pneumococcal disease and AMR with emergence of isolates with MDR phenotype despite is of concern. In the absence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.